IP Library Granted Patent US 8,742,091
Granted Patent B2
US 8,742,091 · App. 10/481,511 · Granted Jun 3, 2014

Method of promoting nucleic acid transfer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,742,091
App. No.
10/481,511
Granted
Jun 3, 2014
Kind
B2
Abstract

Means for transferring efficiently a desired nucleic acid into a cell is provided. The present invention comprises using a complex comprising a collagen or a collagen derivative, and a desired nucleic acid.

Claims (10)

1. A pharmaceutical preparation for administration to a living body comprising a solution of an electrostatic complex consisting essentially of a double-stranded RNA and a water-soluble atelocollagen, wherein said complex facilitates the transfer of said double-stranded RNA to a target tissue or a target organ and said complex exhibits a major axis of 100 μm or less in length.

2. The preparation according to claim 1 , wherein the double-stranded RNA is 5-30 nucleotides in length.

3. The preparation according to claim 1 , wherein the double-stranded RNA is an RNA derivative.

4. The preparation according to claim 1 , wherein the double-stranded RNA is an RNA comprising a phosphorothioate bond.

5. The preparation according to claim 1 , wherein the double-stranded RNA is an RNA comprising an internucleotide comprising a phosphate, sugar or base moiety chemically modified to avoid enzymatic degradations.

6. A pharmaceutical preparation for administration to a living body comprising a solution of an electrostatic complex consisting essentially of an a double-stranded RNA and a water-soluble atelocollagen, wherein said complex facilitates the transfer of said double-stranded RNA to a target tissue or a target organ and said complex exhibits a major axis of 10 μm or less in length.

7. The preparation according to claim 6 , wherein the double-stranded RNA is 5-30 nucleotides in length.

8. The preparation according to claim 6 , wherein the double-stranded RNA is an RNA derivative.

9. The preparation according to claim 6 , wherein the double-stranded RNA is an RNA comprising a phosphorothioate bond.

10. The preparation according to claim 6 , wherein the double-stranded RNA is an RNA comprising an internucleotide comprising a phosphate, sugar or base moiety chemically modified to avoid enzymatic degradations.

Assignments (6)
CHANGE OF NAME Recorded May 27, 2022
From: SUMITOMO DAINIPPON PHARMA CO., LTD.
To: SUMITOMO PHARMA CO., LTD.
Reel/Frame 060044/0480 →
CHANGE OF NAME Recorded Oct 17, 2014
From: DAINIPPON SUMITOMO PHARMA CO., LTD.
To: SUMITOMO DAINIPPON PHARMA CO., LTD.
Reel/Frame 034013/0937 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2010
From: KOKEN CO., LTD.
To: NATIONAL CANCER CENTER
Reel/Frame 024775/0933 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2010
From: DAINIPPON SUMITOMO PHARMA CO., LTD.
To: NATIONAL CANCER CENTER
Reel/Frame 024777/0553 →
MERGER Recorded Dec 16, 2005
From: SUMITOMO PHARMACEUTICALS COMPANY, LTD.
To: DAINIPPON SUMITOMO PHARMA CO., LTD.
Reel/Frame 017089/0420 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2003
From: TERADA, MASAAKI; OCHIYA, TAKAHIRO; ASO, YU; HONMA, KIMI; SANO, AKIHIKO; NAGAHARA, SHUNJI
To: SUMITOMO PHARMACEUTICALS COMPANY, LIMITED; KOKEN CO., LTD.
Reel/Frame 015600/0718 →